Frank P. Bymaster

16.0k citations

141 papers · 12.7k indexed · 5 hit papers · h-index 57

Impact in

Cellular and Molecular Neuroscience top 0.1%
- Neuroscience and Neuropharmacology Research
- Neurotransmitter Receptor Influence on Behavior
Biological Psychiatry top 0.2%
- Tryptophan and brain disorders

Papers in

Cellular and Molecular Neuroscience 96
- Neuroscience and Neuropharmacology Research 56
- Neurotransmitter Receptor Influence on Behavior 55
- Neuropeptides and Animal Physiology 13
Pharmacology 33
- Treatment of Major Depression 22

Co-authors: David T. Wong Christian C. Felder Kenneth W. Perry David L. McKinzie Jong S. Horng Bryan B. Molloy Jürgen Wess George G. Nomikos
Journals: Life Sciences (17 papers)Journal of Pharmacology and Experimental Therapeutics (8 papers)Neuropsychopharmacology (7 papers)Schizophrenia Research (6 papers)Journal of Medicinal Chemistry (6 papers)
Partner nations: United States Denmark United Kingdom

In The Last Decade

Frank P. Bymaster

139 papers receiving 12.2k citations

Hit Papers

5 papers align trajectories log scale

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder 2002 · 897 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2002 Neuropsychopharmacology
2001 Proceedings of the National Academy of Sciences
1997 Archives of Neurology
1996 Neuropsychopharmacology
1974 Life Sciences

Peers

Countries citing papers authored by Frank P. Bymaster

Since Specialization

Citations

This map shows the geographic impact of Frank P. Bymaster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank P. Bymaster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank P. Bymaster more than expected).

Fields of papers citing papers by Frank P. Bymaster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank P. Bymaster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank P. Bymaster. The network helps show where Frank P. Bymaster may publish in the future.

Co-authors

The 25 scholars most cited alongside Frank P. Bymaster, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frank P. Bymaster Line = papers co-authored together Frank P. Bymaster links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity Synapse ·Krystyna Gołembiowska, Mahika Lunker, Frank P. Bymaster	2011	26
2	Allosteric modulation of the muscarinic M ₄ receptor as an approach to treating schizophrenia Proceedings of the National Academy of Sciences ·Wai‐Yee Chan, David L. McKinzie, Suchira Bose, S.N. Mitchell, Jeffrey M. Witkin, R. C. Thompson, Arthur Christopoulos, Sebastian Lazareno, N.J.M. Birdsall, Frank P. Bymaster, Christian C. Felder	2008	170
3	Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia American Journal of Psychiatry ·Anantha Shekhar, William Z. Potter, Jeffrey Lightfoot, A. Petty, Sanjay Dubé, Craig Mallinckrodt, Frank P. Bymaster, David L. McKinzie, Christian C. Felder	2008	429
4	Treatment of glossodynia with olanzapine Journal of the American Academy of Dermatology ·Eduardo Augustus Vicino dos Santos, Ginat W. Mirowski, John Kennedy, Frank P. Bymaster	2004	17
5	New approaches to developing antidepressants by enhancing monoaminergic neurotransmission Expert Opinion on Investigational Drugs ·Frank P. Bymaster, Robert K. McNamara, Pierre V. Trân	2003	45
6	Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double‐blind controlled trial International Journal of Geriatric Psychiatry ·John Kennedy, Dilip V. Jeste, Christopher Kaiser, S. Golshan, Gerald A. Maguire, Gary D. Tollefson, T.M. Sanger, Frank P. Bymaster, Bruce J. Kinon, Martín Dossenbach, J. A. Gilmore, Alan Breier	2003	30
7	Use of M1–M5 Muscarinic Receptor Knockout Mice as Novel Tools to Delineate the Physiological Roles of the Muscarinic Cholinergic System Neurochemical Research ·Frank P. Bymaster, David L. McKinzie, Christian C. Felder, Jürgen Wess	2003	156
8	The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions British Journal of Pharmacology ·Eleni T. Tzavara, Richard J. Davis, Kenneth W. Perry, Xia Li, Craig R. Salhoff, Frank P. Bymaster, Jeffrey M. Witkin, George G. Nomikos	2003	231
9	Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study Neuropsychopharmacology ·Stephan Chalon, Charley Adams Merrill, François Vandenhende, P. R. Bieck, Frank P. Bymaster, CAUWELS RGEC, Joanneke Prenger, William Z. Potter	2003	82
10	Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor Journal of Pharmacology and Experimental Therapeutics ·Amy C. Porter, John‐Michael Sauer, Michael D. Knierman, Gerald W. Becker, Michael J. Berna, Jingqi Bao, George G. Nomikos, Alireza Aliarb, Frank P. Bymaster, Qian LinZhao, Christian C. Felder	2002	441
11	Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proceedings of the National Academy of Sciences ·Yansheng Du, Zhizhong Ma, Suizhen Lin, Richard Dodel, Feng Gao, Kelly R. Bales, Kuei-Hui Lin, Eyassu Chernet, Ken Perry, David L. Nelson, De An Yang, Lee A. Phebus, Frank P. Bymaster, Steven M. Paul Hit paper breakdown →	2001	655
12	Current issues in the psychopharmacology of schizophrenia Lippincott Williams & Wilkins eBooks ·Alan Breier, P. Tran, John M. Herrera, Gary D. Tollefson, Frank P. Bymaster	2001	31
13	A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data International Journal of Geriatric Psychiatry ·John Kennedy, Frank P. Bymaster, Leslie M. Schuh, David O. Calligaro, George G. Nomikos, Christian C. Felder, Catherine K. P. Wan, Bruce J. Kinon, Robert W. Baker, Donald P. Hay, Helmut Roth, Martín Dossenbach, Christopher Kaiser, Charles M. Beasley, John H. Holcombe, Mark B. Effron, Alan Breier	2001	29
14	Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine European Journal of Pharmacology ·Frank P. Bymaster, Julie F. Falcone, Hans-J√∂rg Bart, John Kennedy, Kathryn W. Schenck, Neil W. DeLapp, Marlene L. Cohen	2001	103
15	The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus European Journal of Pharmacology ·Eleni T. Tzavara, Kenneth W. Perry, Dana E. Rodriguez, Frank P. Bymaster, George G. Nomikos	2001	62
16	The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease International Journal of Geriatric Psychiatry ·John Kennedy, Anthony J. Zagar, Frank P. Bymaster, George G. Nomikos, Paula T. Trzepacz, J. A. Gilmore, 閔錫元, Alan Breier, Gary D. Tollefson	2001	27
17	Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex Acta Neurobiologiae Experimentalis ·Kenneth W. Perry, Frank P. Bymaster, Gary D. Tollefson, Celesta A. Steinmetz	1999	3
18	Arachidonic Acid Release in Cell Lines Transfected with Muscarinic Receptors Cellular Signalling ·Frank P. Bymaster, David O. Calligaro, Julie F. Falcone	1999	16
19	Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects Brain Research ·Frank P. Bymaster, O. HUJII, Steven Peters, Wei Zhang, John S. Ward, Charles H. Mitch, David O. Calligaro, Celia A. Whitesitt, Neil W. DeLapp, Harlan E. Shannon, Karin Rimvall, Lone Jeppesen, Malcolm J. Sheardown, Anders Fink‐Jensen, Per Sauerberg	1998	56
20	Functionally selective M1 muscarinic agonists. 3. Side chain and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles Journal of Medicinal Chemistry ·John S. Ward, Chu Trang, David O. Calligaro, Frank P. Bymaster, Harlan E. Shannon, Barry D. Sawyer, Abhinaw Sai Erri Pradeep, Jack B. Deeter, Steven Peters	1995	24

About Frank P. Bymaster

Frank P. Bymaster is a scholar working on Cellular and Molecular Neuroscience, Pharmacology, Psychiatry and Mental health, Biological Psychiatry and Molecular Biology, having authored 141 papers that have together received 12.7k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (72 papers), Neuroscience and Neuropharmacology Research (56 papers), Neurotransmitter Receptor Influence on Behavior (55 papers), Treatment of Major Depression (22 papers), Neuropeptides and Animal Physiology (13 papers), Ion channel regulation and function (12 papers), Schizophrenia research and treatment (11 papers) and Attention Deficit Hyperactivity Disorder (8 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (6.6k citations), Biological Psychiatry (879 citations), Psychiatry and Mental health (3.1k citations), Pharmacology (3.1k citations) and Behavioral Neuroscience (345 citations). Frank P. Bymaster has collaborated with scholars based in United States, Denmark and United Kingdom. Frequent co-authors include David T. Wong, Christian C. Felder, Kenneth W. Perry, David L. McKinzie, Jong S. Horng, Bryan B. Molloy, Jürgen Wess, George G. Nomikos, Julie F. Falcone and David T. Wong. Their work appears in journals such as Life Sciences, Journal of Pharmacology and Experimental Therapeutics, Neuropsychopharmacology, Schizophrenia Research and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact